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Background: Clinical observations suggest thatMycobacterium avium complex (MAC) andMycobacterium abscessus complex (MABSC) may affect
cystic ﬁbrosis (CF) patients with different characteristics and risk factors, but this has never been demonstrated within a single prospective cohort.
Methods:We studied 50 MABSC-positive and 23 MAC-positive patients from a French prevalence study of non‐tuberculous mycobacteria (NTM)
in CF. Risk factors speciﬁcally associated with MABSC and MAC were analyzed by nested case–control studies, with two NTM-negative controls
matched by age, sex and center for each case.
Results:MAC-positive patients were signiﬁcantly older than MABSC-positive patients (mean [SD] age, 23.1 [10.2] vs 17.4 [8.3] years, p=0.013),
and were also older at CF diagnosis (mean [SD] age, 12.9 [16.1] vs 3.1 [7.7] years, p=0.015); they tended to be less frequent of the ΔF508/ΔF508
genotype (33.3 vs 61.1%, p=0.17) and to use pancreatic extracts less frequently (82.4 vs 97.6%, p=0.07). Risk factors identiﬁed by multivariate
analysis were: i) in the MAC case–control study, an older age at CF diagnosis (p=0.004); ii) in the MABSC case–control study, at least one course
of intravenous antibiotics (p=0.01) and more frequent isolation of Aspergillus (p=0.03).
Conclusions: MAC affects adult patients with a mild form of CF, whereas MABSC affects younger patients with more severe CF and more
frequent intravenous antimicrobial treatment.
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Since the 1990s, an increasing number of studies have
reported the isolation of non-tuberculous mycobacteria (NTM)
from the respiratory tract of patients with cystic fibrosis (CF)
[1–7]. NTM prevalence surveys worldwide show that
Mycobacterium avium complex (MAC) and Mycobacterium
abscessus complex (MABSC) account for over 95% of cases of
NTM lung disease in CF patients [3,4,6,7]. MAC, a member of
the slowly growing mycobacteria subgroup, is the most
prevalent among such cases in North America [3]. MABSC, a
member of the rapidly growing mycobacteria subgroup,
however, is more prevalent than MAC in Western Europe [6,7]
and Israel [4].
MAC respiratory infection seems to have only a small effect,
if any, on the health of CF patients. Indeed, the large North
American multicenter study of NTM in CF showed that
NTM-positive patients (mostly MAC-positive) had better
pulmonary function than NTM-negative controls [3].
MABSC-positive patients, by contrast, frequently have severe,
sometimes fatal, lung disease [5,8–11]. Our own and other
studies have suggested that these differences between
MAC-positive and MABSC-positive patients are linked to a
particularly high degree of virulence of MABSC in CF patients
[12–14]. However, some findings suggest that there are
differences between the CF populations affected by MAC and
MABSC, which may substantially affect the severity of
mycobacterial lung disease in these patients. Unlike MAC,
MABSC infects young children [7,15] and may be associated
with allergic bronchopulmonary aspergillosis and systemic
steroid therapy [16]. In the North American multicenter study,
Pseudomonas aeruginosa was less frequent in NTM-positive
patients (mostly MAC-positive, see above) than in NTM-
negative controls [3].
The question of whether MABSC and MAC “target”
different subpopulations of patients has never been addressed
in multicenter studies, due to the small numbers of cases,
recruitment bias (for example, study populations in which
patients are mostly children or mostly adults) or the retrospec-
tive nature of the study. We recently carried out a large survey
of NTM in French CF patients, which included almost 1600
subjects [6]. MABSC and MAC were the most common NTM,
and were the only NTM associated with being positive for
American Thoracic Society (ATS) bacteriological criteria for
NTM lung disease. Here, we compared the characteristics of
the MABSC-positive and MAC-positive patients from this
cross-sectional survey, and further investigated the risk factors
associated with infection by each organism in two nested case–
control studies.
2. Patients and methods
2.1. The French NTM prevalence study
The 2004 French NTM prevalence study included 1582 CF
patients (mean age, 18.9 years; extremes, 4 months to 82 years)
from 41 of the 49 French CF centers (17 adult centers, 20pediatric centers and four mixed adult and pediatric centers)
between January 1st 2004 and December 31st 2004 [6]. This
survey included all patients capable of providing at least three
sputum samples (or other respiratory specimens) for NTM
analysis, with no age limit. Samples were decontaminated with
the two-step N-acetyl-L-cysteine-NaOH-oxalic acid method as
previously described [6,7].
2.2. The French cystic fibrosis registry
Since 1992, individual medical and social data for CF
patients attending the 49 national CF centers in France have
been obtained annually using a standardized questionnaire. The
chief medical officer from each center filled in patient data
sheets during annual check-ups and data were entered into a
national database. All patients, or their parents if they were
children, gave their informed consent, and an internal review
board from the Observatoire National de la Mucoviscidose
approved the study.
2.3. Comparison of characteristics of MABSC-positive and
MAC-positive patients
All MABSC-positive and MAC-positive patients (at least
one sample positive for MABSC or MAC, respectively) from
the French NTM prevalence study were included in this
analysis. Two MABSC-positive patients who were also
positive for other NTM species (only one positive sample
found for each case) were not excluded from the MABSC
group. Demographic, clinical and laboratory data were obtained
from the national CF registry. The chi-square test (or Fisher's
exact test if necessary) was used for comparisons of qualitative
variables, and Student's test for quantitative variables (STATA
software Version 9, StataCorp LP). Statistical significance was
accepted for pb0.05.
2.4. Nested case–control studies of risk factors associated with
MABSC and MAC
The case–control studies included patients who were
positive for MAC only or for MABSC only, with two
NTM-negative controls matched by age (controls born within
±2, 5 and 10 years of the birth date for cases aged 0–15, 16–29
and≥30, respectively), sex and center for each case. When
more than two eligible controls were found for one case, the
controls were selected at random. Only cases and controls with
data available from the national registry for both 2003 and 2004
were included in the case–control study.
The risk factors studied included items related to the
diagnosis of CF (age at diagnosis, CFTR genotype) and the
following parameters, collected the year before the patients were
recruited into the French prevalence study: body mass index
(BMI) and forced expiratory volume in one second (FEV1) at the
annual check-up (both measured at the same time during the last
consultation or last hospitalization during the year considered);
insulin-dependent diabetes mellitus; sputum microbiology
(P. aeruginosa, methicillin-resistant Staphylococcus aureus,
Table 1
Comparative analysis of MABSC-positive and MAC-positive patients from the French NTM survey.
Characteristics MABSC-positive patients
(n=50)
MAC-positive patients
(n=23)
p-value
Sex ratio 0.79 0.53 0.64
Mean age (SD) at inclusion, years 17.4 (8.3) 23.1 (10.2) 0.013
Mean age (SD) at CF diagnosis, years 3.1 (7.7) 12.9 (16.1) 0.015
ΔF508/ΔF508 a 61.1%
(n=36)
33.3%
(n=12)
0.11
Mean (SD) BMI, kg/m2 18.2 (3.3)
(n=36)
19.1 (3.3)
(n=17)
0.37
Mean (SD) FEV1, % predicted 53.6 (19.4)
(n=30)
62.2 (24.7)
(n=15)
0.20
Mean (SD) sweat chloride, mM/L 110 (30.3)
(n=28)
100.3 (32.8)
(n=14)
0.35
Use of pancreatic extracts a 97.6%
(n=42)
82.4%
(n=17)
0.07
Mean (SD) no. of days of hospitalization b 14.7 (44.4)
(n=33)
7.9 (21.0)
(n=17)
0.55
P. aeruginosa a,c 57.5%
(n=40)
50.0%
(n=16)
0.77
MSSA a,c 50.0%
(n=40)
62.5%
(n=16)
0.55
MRSA a,c 20.0%
(n=40)
12.5%
(n=16)
0.70
Aspergillus sp. a,c 37.5%
(n=40)
31.3%
(n=16)
0.76
Abbreviations: NA, not available; SD, standard deviation; MABSC, M. abscessus complex; MAC, M. avium complex; BMI, body mass index; FEV1, forced
expiratory volume in one second.
a Frequency; (): total no. evaluated.
b The year preceding inclusion in the study.
c At least one positive sample in the year before inclusion.
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bronchopulmonary aspergillosis (ABPA); number of inpatient
hospitalizations; number of intravenous antibiotic courses;
long-term (≥3 months) use of inhaled therapies (antibiotics,
rhDnase, steroids and bronchodilators); azithromycin mainte-
nance treatment; long-term (≥3 months) use of systemic
steroids and non-steroid anti-inflammatory (NSAI) drugs.
Cases and controls were compared using the likelihood ratio
test. MABSC- and MAC-associated risk factors were analyzed
by estimating univariate and multivariate odds ratios (ORs)
with 95% confidence intervals (95% CI), using conditional
logistic regression [17]. P-values were assessed by the
likelihood ratio test (univariate analysis) and the Wald test
(multivariate analysis). All factors with a p-value≤0.2 in the
univariate analysis were included in the multivariate analysis.
Exact tests were used when necessary (SAS/STAT software,
version 9.1, SAS Institute Inc., Cary, NC). We considered
associations with a p-valueb0.05 to be statistically significant.
3. Results
3.1. Characteristics of MAC-positive and MABSC-positive
patients
Of the 1582 patients included in the multicenter French survey
of NTM in CF, 50 had at least one sample that was found positive
for MABSC (MABSC-positive patients), and 23 for MAC
(MAC-positive patients); 80% (40/50) of MABSC-positivepatients and 73.9% (17/23) of MAC-positive patients met ATS
bacteriological criteria for NTM lung disease [18].
As shown in Table 1, MAC-positive patients were signifi-
cantly older at NTM diagnosis (mean [SD] age, 23.1 [10.2] vs
17.4 [8.3] years, p=0.013) and at CF diagnosis (mean [SD] age,
12.9 [16.1] vs 3.1 [7.7] years, p=0.015) than MABSC-positive
patients. MAC-positive patients also showed a trend towards
being less frequent of the ΔF508/ΔF508 genotype (33.3 vs
61.1%, p=0.17) and for less frequent use of pancreatic extracts
(82.4 vs 97.6%, p=0.07) than MABSC-positive patients.
We analyzed the distribution of MAC-positive and
MABSC-positive patients as a function of age at CF diagnosis.
The distribution patterns differed considerably between the two
subgroups (Fig. 1). Nearly 90% ofMABSC-positive patients were
diagnosed for CF before 10 years of age and only about 5% after
19 years. By contrast, less than 60% of MAC-positive patients
were diagnosed for CF before 10 years of age; and one third were
diagnosed after 19 years of age and one quarter after 30.
3.2. MAC case–control study
Ten of the 23 MAC-positive patients were excluded from the
nested MAC case–control study (medical history not available, 6
patients; 2003 data not available, 4 patients). We thus included 13
MAC cases, all fulfilling ATS bacteriological criteria for NTM
lung disease [18], and 26matched controls. Cases and controls had
the same sex ratio (M/F, 0.3) and comparable ages (mean [CI 95%]
age, 22.8 [18.6–27.1] and 23.3 [19.1–28.3] years, respectively).
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Fig. 1. Distribution of MAC-positive and MABSC-positive patients as 325 a
function of age at CF diagnosis.
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univariate analysis was older age at CF diagnosis (Table 2). A
negative association was found for the use of inhaled bronchodi-
lators in the year before inclusion in the study (table). Among the
factors tested by multivariate analysis (p-value≤0.2 in the
univariate analysis), only greater age at CF diagnosis was found
to be significantly associated with MAC (Table 2). This prompted
us to compare the circumstances of CF diagnosis in MAC cases
and their controls: intestinal symptoms (which are associated with
early diagnosis) were significantly less likely in MAC cases
(Supplemental file, Table 1).
3.3. MABSC case–control study
Twenty of the 50 MABSC-positive patients were excluded
from the nested MABSC case–control study (medical history
not available, 9 patients; 2003 data not available, 8 patients;
positivity for other NTM, 2 patients; discordant sex data, 1
patient). We thus included 30 MABSC cases, all fulfilling ATS
bacteriological criteria for NTM lung disease [18], and 60
controls. Cases and controls had the same sex ratio (M/F, 1.0)
and comparable ages (mean [CI 95%] age, 17.3 [14.7–19.9]
and 17.4 [15.6–19.2] years, respectively). In univariate
analysis, MABSC showed a positive association with admin-
istration of at least one course of i.v. antibiotics in the preceding
year (Table 3). None of the other risk factors studied were
found to be significantly associated with MABSC. Among the
factors tested by multivariate analysis (p-value≤0.2 in the
univariate analysis), only two showed a positive association
with MABSC: i) at least one i.v. antibiotic course in the year
before inclusion in the study; ii) isolation of Aspergillus the
year before inclusion in the study (Table 3). Two other factors
showed a negative association: i) FEV1b40% predicted the
year before inclusion in the study; ii) inhaled steroids taken the
year before inclusion in the study (Table 3).
4. Discussion
In this study, we used the large, multicenter French survey
of NTM in CF [6], which allowed, for the first time,
comparisons between MAC-positive and MABSC-positivepatients from the same CF population in the same year.
Recruitment biases were minimized because the French NTM
study included all patients capable of providing three (or more)
sputum samples for NTM analysis, with no age limit and no
selection according to the clinical status of the patients.
Moreover, information was collected independently from the
national CF registry and only data from this register were used.
For the analysis of risk factors, appropriate control groups were
obtained by matching cases and controls for age, gender and
center. Age and gender need to be taken into account because
they are significantly associated with NTM in CF patients [6,7].
However, our preliminary findings using data from the French
CF registry showed substantial differences in the therapeutic
management of patients between participating centers (e.g.,
frequency of use of aerosols or long-term azithromycin). Also,
there may be significant differences concerning the environ-
mental exposure to NTM between patients attending centers in
different geographical regions [19]. Thus we considered it
important to exclude any potential ‘center effect’, particularly
as this issue has been overlooked in previous studies.
Our results showed a clear tendency of MAC to infect adults
with mild CF. With a mean age of 23.1 years, MAC-positive
patients were significantly older than MABSC-positive patients
(17.4 years). MAC was only very rarely isolated from patients
younger than 10 years of age; nearly 75% of MAC-positive
patients were 16 years old or older. This group of patients could
also be clearly distinguished by their older age at CF diagnosis
(mean age 12.9 years vs 3.1 years for MABSC-positive
patients), a finding that has never been reported previously to
our knowledge. One third of MAC-positive patients were
diagnosed for CF only after 19 years of age. In multivariate
analysis, the diagnosis of CF at an older age was the only risk
factor associated with isolation of MAC. This finding is
consistent with MAC preferentially infecting a subpopulation
of patients with a less severe form of CF, which may
consequently be detected at a later age. The link between
MAC and a less severe form of CF is also consistent with the
less frequent use of pancreatic extracts in MAC-positive patients.
It remains unclear why a less severe form of CF disease and/
or late diagnosis of CF disease may predispose patients to
infection by MAC. It is possible that antibiotic treatments may
prevent the development of MAC in the respiratory tract
(“beneficial” effect of antibiotics), but not MABSC (see
below). It is also possible that late diagnosis of CF results in
delayed and less stringent application of the appropriate
hygiene and control measures [20]. MAC is present in a wide
variety of environmental settings, including water, soil and dust
[19]. A recent study found high levels of MAC rRNA
sequences in showerhead biofilms [21]. Recommendations on
the home environment (regular de-scaling and disinfection of
lavatories and bathroom fittings, etc.) (http://vaincrelamuco.
org) may thus help to reduce the risk of acquiring MAC.
Unlike MAC, MABSC tended to infect children and
adolescents with a more severe form of CF (more frequent
ΔF508/ΔF508 genotype and use of pancreatic extracts, lower
FEV1 values, longer hospital stays the year before inclusion),
although differences were not significant. In multivariate analysis,
Table 2
Analysis of risk factors associated with MAC.
Risk factors Cases (n=13) Controls (n=26) Univariate OR
[CI 95%]
p-value Multivariate OR
[CI 95%] a
p-value
Mean age at CF diagnosis, years [CI 95%] b 13.3 [4.0–22.6]
n=13
3.3 [0.8–5.5]
n=25
1.2 [1.0–1.4] 0.004 1.2 [1.0–1.4] 0.004
ΔF508/ΔF508 c 3/10 (30) 13/24 (54.17) 0.3 [0.08–1.5] 0.1 NS
BMIb20 c 7/13 (53.85) 19/25 (76.0) 0.4 [0.09–1.8] 0.2 NS
FEV1b40% predicted c 2/13 (15.38) 8/25 (32.0) 0.4 [0.08–2.3] 0.3 NI
ID diabetes mellitus c 0/13 (0) 1/26 (3.9) d – NI
Pseudomonas aeruginosa c,e 6/13 (46.15) 16/26 (61.54) 0.5 [0.1–2.1] 0.3 NI
MRSA c,e 3/13 (23.08) 4/26 (15.38) 1.6 [0.3–8.4] 0.6 NI
Aspergillus c,e 8/13 (61.54) 11/26 (42.31) 3.1 [0.6–16.9] 0.2 NS
Treated ABPA c 3/13 (23.08) 4/26 (15.38) 2 [0.3–14.2] 0.5 NI
At least one hospital stay c 3/11 (27.27) 9/26 (34.62) 0.6 [0.1–3.5] 0.6 NI
At least one i.v. antibiotic course c 7/13 (53.85) 16/26 (61.54) 0.7 [0.2–2.9] 0.6 NI
Inhaled antibiotics c,f 3/13 (23.08) 11/26 (42.31) 0.4 [0.07–1.9] 0.2 NS
Inhaled rhDnase c,f 5/13 (38.46) 12/26 (46.15) 0.7 [0.2–3.1] 0.6 NI
Inhaled steroids c,f 2/13 (15.38) 9/26 (34.62) 0.4 [0.07–1.9] 0.2 NS
Inhaled bronchodilators c,f 3/13 (23.08) 15/26 (57.69) 0.1 [0.01–0.9] 0.01 NS
Long-term azithromycin c,f 2/13 (15.38) 11/25 (44.0) 0.2 [0–1.1] 0.07 NS
Oral steroids c,f 1/13 (7.69) 1/22 (4.55) 1.4 [0.08–23.6] 0.8 NI
Oral NSAI c,f 0/13 (0) 0/24 (0) – d – NI
Abbreviations: CF, cystic fibrosis; 95% CI, 95% confidence interval; OR, odds ratio; BMI, body mass index; FEV1, forced expiratory volume in one second; ID,
insulin-dependent; MRSA, methicillin-resistant Staphylococcus aureus; ABPA, allergic bronchopulmonary aspergillosis; i.v., intravenous; NSAI, non‐steroid
anti-inflammatory drugs; NI, variables not included; NS, not significant.
a Only variables for which univariate analysis showed a p-value lower than 0.2 (bold) were tested by multivariate analysis.
b Linearity was checked: a one unit increase corresponds to a one year increase.
c No./total no. evaluated (%).
d The Log-likelihood ratio test was not applicable.
e At least one positive sputum sample.
f At least three consecutive months.
Table 3
Analysis of risk factors associated with MABSC.
Risk factors Cases (n=30) Controls (n=60) Univariate OR
[CI 95%]
p-value Multivariate OR
[CI 95%] a
p-value
Mean age at CF diagnosis, years [CI 95%] b 2.6 [0.12–4.99]
n=29
2.7 [1.41–4.01]
n=56
1.0 [0.9–1.1] 1.0 NI
ΔF508/ΔF508 c 16/27 (59.26) 34/53 (64.15) 0.7 [0.3–1.4] 0.3 NI
BMIb20 c 19/28 (67.86) 45/59 (76.27) 0.6 [0.2–2.1] 0.4 NI
FEV1b40% predicted c 2/26 (7.69) 10/56 (17.86) 0.4 [0.09–2.0] 0.2 0.04 [0.002–1.03] 0.05
ID diabetes mellitus c 3/27 (11.11) 2/59 (3.39) 3 [0.5–18.0] 0.2 NS
Pseudomonas aeruginosa c,d 18/30 (60) 34/58 (58.6) 1.1 [0.5–2.6] 0.9 NI
MRSA c,d 5/30 (16.67) 8/58 (13.79) 1.2 [0.4–3.6] 0.8 NI
Aspergillus c,d 14/30 (46.67) 18/58 (31.03) 2.2 [0.8–5.8] 0.1 6.0 [1.2–29.4] 0.03
Treated ABPA c 6/27 (22.22) 6/59 (10.17) 2.4 [0.6–8.7] 0.2 NS
At least one hospital stay c 6/25 (24) 21/51 (41.18) 0.5 [0.1–1.8] 0.3 NI
At least one i.v. antibiotic course c 23/29 (79.31) 34/57 (59.65) 2.8 [1.0–8.1] 0.04 13.7 [1.7–109.8] 0.01
Inhaled antibiotics c,e 15/30 (50.0) 35/58 (60.34) 0.7 [0.3–1.6] 0.4 NI
Inhaled rhDnase c,e 18/30 (60.0) 32/58 (55.17) 1.3 [0.5–3.7] 0.6 NI
Inhaled steroids c,e 8/30 (26.67) 26/58 (44.83) 0.4 [0.1–1.2] 0.08 0.06 [0.006–0.7] 0.03
Inhaled bronchodilators c,e 10/30 (33.33) 25/58 (43.10) 0.6 [0.2–1.7] 0.4 NI
Long-term azithromycin c,e 10/28 (35.71) 23/58 (39.66) 0.9 [0.3–2.3] 0.8 NI
Oral steroids c,e 1/27 (3.70) 2/54 (3.7) 0.6 [0.05–7] 0.7 NI
Oral NSAI c,e 2/30 (6.67) 3/57 (5.26) 1.2 [0.2–7.0] 0.9 NI
Abbreviations: CF, cystic fibrosis; 95% CI, 95% confidence interval; OR, odds ratio; BMI, body mass index; FEV1, forced expiratory volume in one second; ID,
insulin-dependent; MRSA, methicillin-resistant Staphylococcus aureus; ABPA, allergic bronchopulmonary aspergillosis; i.v., intravenous; NSAI, non‐steroid
anti-inflammatory drugs.
a Only variables for which univariate analysis showed a p-value lower than 0.2 (bold) were tested by multivariate analysis.
b Linearity was checked: a one unit increase corresponds to a one year increase.
c No./total no. evaluated (%).
d At least one positive sputum sample.
e At least three consecutive months.
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cases were more likely to have received intravenous antimicrobial
treatment. The increased use of intravenous antimicrobial therapy
may provide an ideal terrain for MABSC infection. MABSC is
one of the most resistant mycobacterial species, and expresses
natural resistance to most intravenous antibiotics commonly used
in cases of CF [22]. The more frequent isolation of the
antibiotic-resistant Aspergillus spp. from MABSC-positive pa-
tients supports this hypothesis. As for some other emerging CF
pathogens [23,24], MABSC infections may thus be a side effect
of intravenous antibiotic treatments. This is consistent with the
results of the Israeli multicenter study, which also found a link
between NTM – mostly MABSC and M. simiae – and the
increased likelihood that patients received intravenous antimicro-
bial treatment [4]. We cannot however exclude the possibility that
the more frequent i.v. antimicrobial treatment is not a cause but
rather a consequence of MABSC infection: such treatment may
be prescribed for infectious symptoms months or even years
before the identification of MABSC.
We did not find a significant positive association between
the presence of MABSC or MAC in sputum and the use of the
other “new” therapeutic approaches to CF such as inhaled
therapies or long-term azithromycin [25,26]. We detected a
negative association between MAC and bronchodilator aerosols
(univariate analysis only), probably due to the fact that MAC
infects subjects with milder forms of CF. Our results do not
however exclude the possibility that positive associations exist
between MABSC or MAC infection and new therapeutic
approaches; indeed, the acquisition of NTM may be associated
with exposure to such treatments months, or even years, earlier.
Indeed, the main limitation of our study is that, like all other
published studies, any such association could have been
missed. Although the therapy administered to any one patient
does not generally change substantially from one year to the
next, particularly when the clinical status is stable, bias of this
type cannot be excluded.
Consistent with the study by Levy et al. [4], we did not
identify ABPA as a significant risk factor for MABSC. This
contrasts with an earlier Israeli study by Mussaffi et al., which
found a significant association between NTM infections –
mostly MABSC infections – and both ABPA and systemic
steroid therapy [16]. These discrepancies may result from
differences in the definitions used or –most probably – from an
inadequate control group in the study by Mussaffi et al.
However, the absence of an association between MABSC and
ABPA (treated or not) is consistent with Aspergillus spp. only
being a marker of exposure to broad-spectrum antibiotics. The
negative association in multivariate analysis between inhaled
steroid therapy and MABSC in the case–control study is also
consistent with these conclusions.
Our results clearly show that not only does the apparent
severity of an NTM infection in a CF patient result from the
severity of the infection itself, but that it also depends on the
severity of CF. In the case of MAC infections, which arise
principally in adults in relatively good health, mycobacterial
infection may be missed. In the case of MABSC infections,
which arise frequently in young children with poor respiratoryfunction and general state, the effect of the mycobacterial
infection can be overestimated. Diagnostic ATS criteria for
NTM lung disease are often difficult to apply to CF patients,
due to overlapping symptoms and radiographic changes
attributable to the CF disease itself [18]. Our data show that it
may be useful to identify diagnostic and prognostic criteria that
are specifically associated with MABSC and MAC in CF
patients, as has previously been attempted for radiological data
[27]. This would help decisions about whether or not to treat,
currently the major issue facing clinicians in the management of
CF patients positive for NTM.
In conclusion, we show that MABSC and MAC target CF
patient populations with different, and even opposite, profiles,
and are associated with independent and different risk factors.
Thus, if we are to progress in the diagnosis, treatment and
prevention of NTM lung infections in CF patients, clinical and
epidemiological studies will be needed in which NTM are no
longer considered as a homogeneous entity.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2012.06.009.
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